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Abstract
Immune responses of the host to any infectious agents vary in controlling the 
pathogens. The process begins by the entry of microorganisms into the host to 
initiate host immune response to understand the type of microorganisms and 
react accordingly for possible elimination of the organisms. In some cases the host 
co-exists with the pathogens or unable to effectively deal with them leading to 
disease condition. Thus, the pathogens establish, multiply and cause disease. The 
review considered the mode of acquisition of infection, pathogenesis and immune 
responses to microbial infection. Other areas included the enhancement of immune 
responses to control infection, immune responses of the host under drug treat-
ment and the control of microbial infection. The understanding of the relationship 
between infectious microbes and the host immune system leading to protective 
immunity or disease state will give much information about treatment and control-
ling of microbial infection in our environment.
Keywords: immune response, host-microbial, pathogens, infectious agents,  
drug treatment
1. Introduction
Several human diseases are caused by pathogenic microorganisms which are 
diverse and are divided into four major groups namely bacteria, viruses, parasites 
and fungi [1]. Thus, different pathogens cause varied diseases. Members in each 
group were classified into subgroups based on unique characteristics they pos-
sess [2]. Bacteria were differentiated based on their staining properties due to 
variation in the cell wall components and those without cell wall, hence there are 
gram-positive, gram-negative, acid-fast and cell wall defective bacteria. These were 
subdivided by their shape (spherical and rod-shaped bacteria), growth requirement 
(e.g. aerobic and anaerobic) among others [3]. Viruses have DNA and RNA with 
each kind having either single-stranded or double-stranded nucleic acid. These 
were further classified by the presence or absence of an outer envelope, shape, size 
and other characteristics [3, 4]. The parasites included protozoa, helminths and 
arthropods. Unlike helminths and arthropods, which were multicellular, the pro-
tozoans were unicellular and conveniently classified by their mode of locomotion. 
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The protozoans included amoebas, ciliates, flagellates and apicomplexans. The 
helminths were classified according to their shape: nematodes (roundworms) and 
platyhelminths (flatworms and tapeworms). The arthropods were also considered 
as vectors of pathogens mainly viruses and bacteria [3, 4]. Finally, the fungi were 
made up of unicellular forms (Saccharomyces cerevisiae) and multicellular forms 
(molds). The molds were subdivided into hyphae and conidia forms [3].
Generally, pathogenic microorganisms are either primary/true pathogens or 
opportunistic pathogens. The primary pathogens were those capable of causing 
diseases in the host irrespective of the host’s immune system. Thus, they cause 
diseases in immunocompetent and immunocompromised individuals and per-
sons with slight imbalances of the immune system. However, the opportunistic 
pathogens mostly included the normal flora and only cause diseases in immuno-
compromised individuals as well as when they occur in parts of the body that were 
not natural to them [5]. When infection occurs, there is interaction between the 
host immune system and the pathogens. The outcome involved either immune 
control towards the infection or disease development with pathological manifesta-
tions due to the inability of the host immune responses to effectively deal with the 
pathogens [5, 6]. Understanding the immune responses to microbial infections 
with or without medication is necessary in the management, control and preven-
tion of infectious diseases. This chapter focuses on the mode of acquiring infec-
tions, pathogenesis and immune responses to microbial infection, enhancement of 
immune responses to control infection, immune responses of the host under drug 
treatment and preventing microbial infection.
2. Modes of transmission of infectious diseases
Infection is the multiplication of pathogens in or on the body of the infected 
host whereas disease is the impairment in the normal function of the host because 
of damage to the host’s cells by the infection [7, 8]. Thus, for infection or disease to 
occur, the pathogens must attach to or enter the body of the host, multiply, evade 
the immune responses, cause damage to the host cells and spread to new hosts. In 
some individuals, the disease is symptomatic while in others, it is asymptomatic. 
The time interval between infection and appearance of the first clinical sign or 
symptoms of disease was known as incubation period and this was the time the 
infection can be spread without the person knowledge [7]. The incubation period 
is influenced by several factors such as dose of a pathogen, route of inoculation, 
rate of replication of infectious agent, host susceptibility and immune responses. 
Hence, incubation period varies among diseases. For instance, non-typhoidal 
Salmonella typhi has incubation period of 10 to 14 days, that of Bordetella pertussis 
is 7 to 10 days, among others [4, 9]. The incubation period is followed by prodro-
mal period whereby microbial agents continuously multiply and the host begins to 
experience general signs and symptoms of illness which are mostly general to be 
associated with a particular disease. The signs and symptoms were due to activa-
tion of the immune system [5]. After the occurrence of the prodromal period is the 
period of illness during which individual feels extremely sick and can easily spread 
the infections followed by the period of decline. The declining period is associated 
with the controlling of the replication of the pathogens resulting in lessening of 
the signs and symptoms of the disease. Thus, individuals feel better at this state. 
This period is followed by the period of convalescence where microbial replication 
stops, and the person fully recovers from the disease. However, in some cases, indi-
viduals who have recovered fully can still spread the infection in the environment 
[5]. What it means is that the immune responses are strong against the pathogens 
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to prevent development of clinical manifestations but are unable to destroy the 
pathogens in the body so the person harbors and spread the infection in the 
environment. Those individuals are called carriers. A typical example is a person 
with typhoid fever. The pathogen was continuously shed in the feces to the exter-
nal environment hence the infection could be acquired through ingestion of fecally 
contaminated food or drinks [10, 11]. Human immunodeficiency virus (HIV) and 
hepatitis B and C carriers could spread the infection through blood products and 
body fluids [12, 13]. Another example was a tuberculosis infected person with mild 
clinical presentations, but persistent cough could spread the infection through air 
before the disease was diagnosed [14]. Vertical transmission through transplacen-
tal infection was also possible (e.g. toxoplasma, rubella, cytomegalovirus, Herpes 
simplex, and other organisms including Treponema pallidum, HIV, parvovirus) 
[15]. There were other infectious diseases such as anthrax, balantidiasis, toxoplas-
mosis, taeniasis and rabies that were zoonotic and could be acquired from animals 
[16, 17]. Insect vectors such as female Anopheles, ticks and sandflies could also 
help spread the infections including malaria, babesiosis, rickettsiosis and leish-
maniasis respectively [18–21]. In summary, infectious diseases can be acquired in 
several ways including horizontal means such as touching contaminated surfaces, 
direct skin contact, body fluids, airborne, vector borne, and ingesting raw/under-
cooked meat. Other mode of transmission includes fecally contaminated food and 
water and vertical transmission among adult and children.
3. Pathogenicity of microbial infection
The ability of a microbe to cause disease is known as pathogenicity and the 
degree or extend of the pathogenicity is termed virulence. Virulence varied from 
mild to severe with varying virulent factors that directly or indirectly play a role in 
pathogenicity and virulence [22]. Hence, some pathogenic microbes are avirulent 
causing diseases only occasionally, moderately virulent that cause mild diseases 
while others are highly virulent causing diseases with severe clinical presentations. 
For a microbe to cause a disease, the pathogens must attach to and/or enter the host 
body with the help of virulent factors and colonize [23–25]. The main attachment 
and entry sites for microorganisms include the skin, conjunctiva, alimentary, respi-
ratory and urinogenital tracts. Some microbes attached to and sometimes penetrate 
the host body surfaces such as the skin and cells (nucleated and non-nucleated) 
using adhesins (proteins) located on the surface of the pathogen [26]. The adhesins 
bind to specific host receptors, which could be transmembrane glycoproteins or 
extracellular matrix proteins. Others entered directly through open surfaces like 
skin wounds, through inhalation, a vector such as bites from infected arthropods, 
mammals like dogs involved in rabies cases and piercing by contaminated devices 
such as needles [25, 27–30]. The conjunctiva is mostly infected by the fingers, face 
towels, flies that settle there among others. Chlamydia trachomatis and Neisseria gon-
orrhea were sexually transmitted pathogens that commonly cause conjunctivitis in 
neonates [31] who acquire the infection from infected cervix during normal birth. 
Not much about the pathogenesis of C. trachomatis is known. However, C. trachoma-
tis is an intracellular pathogen and inhibits phagosome and lysosome fusion when 
it is phagocytosed thereby evading host immune defenses [32]. Mucosal surfaces 
of the respiratory tracts have immune mechanisms and cells that prevent pathogen 
attachment and colonization. Hence, some invading pathogens such as Streptococcus 
pneumoniae could attach to epithelial cells only when the mucocillary and other 
immune mechanisms were defective [33]. However, some pathogens have strong 
attachment structures. For instance, Bordetella pertussis has fimbriae and produces 
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a kind of protein called filamentous haemagglutinin A (FHA) which enable the 
pathogen to attach to the epithelial cells of the bronchia and the lungs [34] thereby 
disrupting the ciliary activity leading to their multiplication, colonization and host 
tissue damage. Mycobacteria tuberculosis is phagocytosed by alveolar macrophages 
in which most die. However, some survive and continue to replicate until the 
macrophages die leading to their release, where some reinfect other cells and some 
enter the blood and lymph circulations; carried to other parts of the body [35]. The 
pathogens of the gastrointestinal tract cannot be overlooked. Helicobacter pylori is 
an important intestinal pathogen that was associated with chronic gastritis, peptic 
ulcer and gastric cancers [36]. It possesses flagella and adhesins for attachment to 
the gastric mucosa. It produces several vital enzymes most notably urease which 
enable the pathogen to survive in the gastric environment for colonization. Urease 
acts on urea and degrades it to form ammonia and carbon dioxide. Ammonia neu-
tralizes the acid in the stomach making the environment favorable for its survival. 
Moreover, H. pylori produces toxins such as vacuolating cytotoxin, and cytotoxin-
associated gene encoded by the vacA and cagA genes respectively [37]. These tox-
ins/proteins induce intense inflammatory responses leading to damage to the host 
tissues. The immune response is unable to eliminate this pathogen hence the use of 
antibiotics for their eradication. Another example is Enterohemorrhagic Escherichia 
coli (EHEC) serotype O157:H7, which is a true human pathogen and causes bloody 
diarrhea, hemorrhagic colitis (HC) and life-threatening complication such as the 
hemolytic-uremic syndrome (HUS). This pathogen is resistant to destruction by the 
gastric acid and so passes the acidic barrier and get to the recto-anal junction (RAJ) 
where it attaches tightly and forms attaching and effacing (A/E) lesions on the RAJ 
mucosal epithelium for colonization [38]. It produces Shiga-like toxins which when 
enters the circulation leads to HUS. Additionally, Giardia lamblia, noninvasive 
parasite possess sucking disc for attaching tightly to the epithelium surface of the 
small intestine leading to inflammatory responses as well as malabsorption due to 
destruction of the villi. The attachment is also aided by lectins, which are found on 
its surfaces and the flagella aid in motility [4].
Regarding the urinogenital tract, it is mostly sterile as a result of frequent 
flushing by urine, hence most invaded pathogens are flushed out and do not get 
access into the system. However, certain pathogens like Neisseria gonorrhea when 
invaded were able to colonize the tract [39]. This results in the infection of mainly 
the cervix, urethra, and rectum. The mouth, nasopharynx and the eye may also be 
affected. The virulent factors included pili, which enable it to attach firmly to the 
epithelial cells of urogenital sites, OPA proteins (adhesives) and IgA proteases [4]. 
It worth noting that women frequently get urinary tract infection than men because 
of the difference in the anatomical structure. Thus, men have longer urethra than 
females.
4.  Microbial infections and the corresponding immune response towards 
their elimination
Infection of the host by the pathogens responses in the host with initial reac-
tion of the innate immune response followed by the adaptive immune responses. 
Infection involving bacteria is associated with various mechanisms to evade or 
survive the host immune response. Some of the bacteria form capsules, complex 
structures which present many diverse antigenic targets to the host body surface 
[40, 41]. The capsules are effective at hiding many bacterial surfaces and prevent-
ing opsonization to enable them circulate systemically within the body. Some of 
these bacteria involved in capsule formation included Streptococcus pneumonia, 
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Haemophilus influenzae, Escherichia coli, and Neisseria meningitides which rely exten-
sively on its capsule to prevent antibody and complement deposition on its surface 
[42] thereby avoiding opsonization and phagocytic clearance.
Viruses also evolve a number of techniques for evading the immune responses 
by avoiding complement system through rearrangement of epitopes in their surface 
proteins. The measles virus prevent antibodies binding to haemagglutinin to initi-
ate complement by the classical pathway [43] presumably because the antigenic 
epitopes were so spaced that effective bridging cannot be obtained between them. 
Human Immunodeficiency Viruses were able to bind to cells through complement 
receptors after fixing complement and also Dengue virus which could enter cells 
through Fc receptors after having bound antibody [44]. Other organisms such as 
Herpes virus saimiri, Trypanosoma cruzi and Schistosoma mansoni [45], captured 
complement control proteins to change their function [46]. However, the immune 
response to microbial pathogens relies on both innate and adaptive components 
and they work together to eliminate the pathogens. Macrophages and dendritic 
cells were found in all body tissues, serving as sentinels in wait for pathogens and 
respond to variety of chemotactic agents that were shed as a result of infection [47]. 
The cells bind the pathogens via phagocytic receptors that initiated the cytoskeletal 
rearrangements and membrane trafficking for phagocytosis [48, 49]. Other innate 
cells like neutrophils, basophils, eosinophils and NK cells contributed together in 
clearing of the pathogens through phagocytosis, cytotoxicity, and the release of 
cytokines to enhance their activities in eliminating the pathogens [50]. The adaptive 
immune cells are made up of B and T lymphocytes, including γδT cells, T reg cells 
and Th17 cells. Microbial antigens are taken up by antigen-presenting cells in the 
peripheral tissues and delivered to the lymph nodes or spleen through the lymph 
or blood, respectively. They are therefore recognized by these adaptive cells and 
differentiate specifically into several types of effector cells, depending on the class 
of pathogens they recognized. The differentiation of lymphocytes into a particular 
effector-cell type and their localization to the site of infection were regulated by 
the innate immune system, generally in the form of cytokines and chemokines [51]. 
The effector cells therefore exhibit their function through cytotoxity as well as the 
release of cytokines which together aid in destroying the pathogens.
5. Enhancement of immune response to control infection
Antigenic features of microbes known as pathogen-associated molecular pat-
terns (PAMPs) are recognized by Pattern Recognition Receptors (PRRs). These 
involve Toll-like receptors (TLRs), NOD-like receptors (NLRs), AIM2-like recep-
tors (ALRs) and RIG-I-like receptors (RLRs) and stimulation with ligands promptly 
potentiated the production of proinflammatory cytokines and chemokines [52] 
which facilitated the clearing of bacterial infections. There was significant reduc-
tion in the number of Haemophilus influenzae and Moraxella catarrhalis bacteria 
recovered from the nasopharynx through intranasal inoculation of monophospho-
ryl lipid A in mice [53]. The use of PRR ligands for Staphylococcus aureus adjuvants 
vaccine formulated with a TLR7 agonist and adsorbed onto alum adjuvant (4CT7-
Staph) conferred about 80–90% protection against four different Staphylococcal 
strains [54]. NOD-like receptors were also important for clearing a variety of 
bacterial infections, including Salmonella Typhimurium, S. flexneri, Pseudomonas 
aeruginosa, and B. pseudomallei [55]. Most often, B. pseudomallei induces NLRC4-
dependent pyroptosis which restricts intracellular bacterial growth. However, the 
activation of NLRP3, upregulates IL-1β, promoted the replication of B. pseudomal-
lei and recruited excessive neutrophils to the lung leading to tissue damage [56]. 
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Identifying small molecules that selectively activate NLRP3 inflammasome and 
prevent cytokine secretion may also be promising new therapeutic strategy.
Most bacterial killing are enhanced by autophagy activity in response to cellular 
stresses, including hypoxia, energy loss, and nutrient deprivation. This process 
provided a mechanism for the adaptation to starvation and regulated cellular 
metabolism and homeostasis [57], therefore play a major role in homeostatic 
maintenance. The use of autophagy as innate immune mechanism for the clearance 
of intracellular pathogens [58] enhances the efficient immune responses in dealing 
with pathogens. Alternatively, bacterial clearance could also occur through LC3-
associated phagocytosis (LAP), which was mediated through single-membrane 
phagocytic vesicles that contain engulfed pathogenic bacteria including Escherichia 
coli, S. Typhimurium, Mycobacterium marinum, and B. pseudomallei [59]. These were 
transiently coated with LC3-II and sirolimus, an mTOR inhibitor, that increased the 
colocalization of the bacteria with LC3 in phagosomes, thereby augmenting phago-
somal maturation and further phagocytosis [60]. Also treatment of macrophages 
with AMG548, a p38 inhibitor, promoted the clearance of M. tuberculosis by induc-
ing autophagy [61]. The host response to hypoxic conditions created by bacterial 
infections regulated by hypoxia-inducible factor (HIF) which [62] drove the 
expression of proinflammatory cytokines that mediated macrophage aggregation, 
invasion, and motility thereby enhancing the intracellular killing of the bacteria 
during replication [63, 64].
Again, macrophages and neutrophils produced reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) molecules that acted as a defense mechanism to 
trigger the clearance of the phagocytosed microorganisms [65]. However, an imbal-
ance in the production and elimination of ROS is associated with human diseases.
6.  Drug treatment regime in microbial infection and the interaction with 
immune response
The treatment of any infections targets the clearing of the pathogens involved 
and allows the immune system to develop and fully functions. Therapeutic strate-
gies for the treatment of microbial infections have mainly relied on the antibiotics 
that target pathogenic proteins, DNA, RNA, or cell wall synthesis. In some cases, 
not all the pathogens are cleared and some may resist clearance. In Tuberculosis 
(TB) infection, effective drugs have been available for decades, but the disease 
remained a major infectious disease at global level [66, 67]. This might be due to 
the emergence of Mycobacterium tuberculosis (Mtb) strains showing resistance to 
some of the most commonly used effective drugs: isoniazid and rifampicin [67]. 
These multi-drug resistant Mtb strains (MDR-TB) were responsible for 0.49 mil-
lion cases of tuberculosis, mostly in India, China and the Russian Federation [67]. 
The interaction between Mtb infection in an immunocompetent host led to latent 
TB infection, with no signs or symptoms of active disease [68]. This involves the 
critical role of host innate and adaptive immune responses in the control of Mtb 
infection. The intrinsic ability of host responses to contain Mtb replication while 
preventing the development of the typical tissue damage, formed the hallmark 
of active TB [69]. There was therefore the persistence and a certain degree of 
replication of Mtb in host tissues in a dynamic equilibrium with the host, which 
in most cases lasted for lifetime [70, 71]. However, the immune responses that 
involve phenotype of immune cells with their chemokines and cytokines secre-
tions responsible for the consequences at local level remains to be determined. 
Eventually, the critical role of the host immune response in the control of Mtb 
replication, or emergence of active disease instead depend on many factors and 
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may be assisted by drug therapy or microbial modulation of the immune system. 
For humans, these interactions could be infection with pathogenic microbes or 
vaccination [72]. Vaccination with Bacillus Calmette-Gue’rin (BCG), an attenuated 
strain of Mycobacterium bovis, protected against tuberculosis (TB), but its effects 
on the immune system extended far beyond specific protection against TB [73]. 
BCG vaccination has been shown to afford nonspecific protection against infection 
by a number of pathogens, including Schistosoma mansoni and Listeria monocyto-
genes [73]. The appearance of carbapenem-resistant Enterobacteriaceae had also 
affected the therapeutic benefit of the carbapenem class of antibiotics, which were 
reserved as a last-line defense [52, 74, 75].
Drug-resistant viral strains has also compromised the effectiveness of treatment, 
or even lead to its failure. Drug-resistant viruses occurred as a result of muta-
tion at high frequencies of the viral RNA or DNA [76]. Their genotypes could be 
advantageous in hosts where the drug was present and could become the dominant 
genotypes in such hosts [77]. Influenza virus also developed resistance to oselta-
mivir drugs through mutations and there might be possible exchange of genetic 
information between resistant and susceptible viral strains [78]. The therapeutic 
options against HIV-1 include more than 20 drugs through their action mechanisms. 
These targeted to four different points of the viral replication cycle such as the 
entry of the virus into the cell, inverse transcription, the integration of viral genetic 
material into the cell nucleus, and maturation of virions [79]. This phenomenon 
has been associated with the high replicative capacity of the virus and the high error 
rate in the transcription of its genetic material. These might be due to the presence 
of specific mutations resulting from pharmacological pressure and suboptimal 
viral suppression under a treatment scheme [80]. Herpes virus infection depended 
upon viral inhibition of several cell functions including the turning off of host 
protein synthesis, inhibition of mRNA splicing, blocking presentation of antigenic 
peptides on the cell surface and apoptosis [81]. Treatment of HSV-infections with 
nucleoside analogs was very common but the development of drug-resistant virus 
from immunosuppress patients with prolonged exposure to the antiviral agent has 
been established [82–84]. Mutations of the herpes viral Thymidine kinase (TK) and 
DNA polymerase (DNApol) occurred and involved in mechanisms of resistance 
to acyclovir and penciclovir [85, 86]. The development of point mutations by the 
pathogens to survive drugs as well as the host immune response involve various 
factors associated with the infection. In some cases, less aggressive chemothera-
peutic regimens substantially reduce the probability of onward transmission of 
resistance without significant changes in host pathology [87, 88]. In contrast, high 
dose aggressive treatment in controlling the resistant populations were effective 
in Staphylococcus aureus infection [89, 90]. There are multitude of results that 
indicate problem of devising general practices for treatment. There could be the 
development of conceptual frameworks to follow in administering aggressive and 
moderate chemotherapy [91], but quantitative systematic analyses are also needed. 
The challenge was to identify among the diverse potential treatment regimens, that 
minimized selection for drug-resistance while not compromising patient health 
[92]. This will go a long way to assist in treating majority of infected people without 
any side effect.
7. Controlling microbial infection: The best way
Currently, the phenomenon of multi-drug resistance due to indiscriminate 
administration of high-doses of antibiotics has been the bane of controlling 
microbial infection. The indiscriminate and inappropriate use of drug in treating 
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infection has also led to significant toxicity in the infected patients, which pres-
ent other challenges to tackle. The environment plays a major role in facilitating 
transmission of several important health care-associated pathogens. These included 
vancomycin-resistant enterococci (VRE), Clostridium difficile, Acinetobacter spp., 
methicillin-resistant Staphylococcus aureus (MRSA) and norovirus [93–95]. These 
pathogens are frequently shed into the environment to contaminate, water and 
surfaces of any objects for days and increase the risk of infection of humans. In 
addition, infection occur through vectors of many pathogens, which spread quickly 
and affect human population.
Together in the environment, microorganisms form complex communities that 
play critical roles in either maintaining the well-being of their hosts or destroying the 
host. In order not to allow their survival to the detriment of the existence of the host, 
they have to be cleared in both the host and the environment. Therefore, several 
treatment means have been developed to control microbial infections and these have 
led to the development of antimicrobial drug resistance pathogens. Addressing this 
challenge, appropriate use of antimicrobials in human medicine is needed. There 
should be a means of ensuring timely production and communication of critical 
diagnostic results and standardized drug susceptibility testing reports in accordance 
with local treatment guidelines [96, 97]. Also, there should be provision of facility-
specific cumulative susceptibility reports for bacterial pathogens against antibiotics, 
daily counseling to clinicians on etiological infection diagnoses and management, 
and interpretation of test results. Targeted therapy of difficult-to-treat resistant 
pathogens and complicated infections are very important guidelines in successful 
treatment of patients. However, some treatment regimens have been developed to 
be very useful to avoid the development of microbial resistance. These included the 
use of nanoparticles to destroy the biofilms and also lessen the doses of antibiotics 
required in treating patients [98]. The development of a recombinant lysis-deficient 
Staphylococcus aureus phage P954, to kill the target cells but not destroy the host cells 
would alleviate the concern about the use of bacteriophages for therapeutic purposes 
[99]. These damping the potential immune response, rapid toxin release by the lytic 
action of phages, and in dose determination difficulty in clinical situations. Phage 
therapy was currently practiced routinely and successfully in countries such as 
Poland and Russia [100] and could be developed rapidly to combat the emergence of 
antibiotic-resistant pathogenic bacteria [101, 102].
Mast cells (MCs) have also been shown to contribute to host–defense responses 
in certain bacterial infections. Treatment with recombinant IL-6 from engrafted 
mast cells enhances bacterial killing and resulted in the control of wound infection 
and normal wound healing [103]. Taken together, host innate immune response will 
be a potential means in boosting the clearing of microbial organisms.
Generally, public health strategies in controlling infectious diseases needed 
proper coordination, planning of infection control activities, post-prescription 
review, and feedback [93, 104, 105]. There should be a team of Clinical 
Microbiologist and well equipped laboratories with experience staff, working 
together to inform and improve individual patient care, contribute to outbreak 
management of infection and provide accurate surveillance data on infectious dis-
eases. This information could be subsequently used in the review of local treatment 
guidelines, the design and evaluation of national health policies [106].
8. Conclusion
The microbial infection involved the use of many strategies by the pathogens 
to survive in the host. These have resulted in the development of drug resistance 
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strains in many pathogens, which persist and continue to be harmful to the host. 
Many treatment strategies have been failing and making it difficult in controlling 
diseases. This requires the development of revised scientific means to successfully 
control infections. Therefore, successful treatment of infections including bacterial 
and viral infections is the enhancement in both the use of antibiotics (for bacterial 
infections), antiviral (viral infections) and the host’s immune defenses. As a result 
of the development of drug resistant strains in many treatment cases the enhance-
ment of mostly innate immune response together with the adaptive immune 
response will go a long way in treating patients without difficulty.
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